文献速递眼底病与葡萄膜炎

年龄相关性黄斑变性治疗相关临床问题与患者重要结局的评估

Evaluation of Clinical Questions and Patient-Important Outcomes Associated With the Treatment of Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

该研究通过改良德尔菲流程,对AAO视网膜/玻璃体专家组、ASRS眼科医生、会议参会者及患者进行多轮问卷,从70个临床问题中筛选出12个高优先级研究问题,其中9个与抗VEGF药物相关;患者还确定了6个最重要的结局指标。

要点

  • 从70个临床问题中,专家组评出17个高度重要,医生进一步评出12个高优先级研究问题。
  • 12个高优先级问题中9个与抗VEGF药物相关。
  • 患者认为33个结局中6个最重要,兼顾疗效与不良事件。

核心结论

  • 四个利益相关群体对12个优先临床问题有较好共识,可用于指导AMD治疗相关研究。

研究设计与样本

  • 采用改良德尔菲流程的多轮横断面问卷调查,纳入AAO视网膜/玻璃体专家组7人、ASRS眼科医生90人、ACRC和Macula 2017会议参会者34人及MD Support患者46人,数据收集于2015年1月20日至2017年1月9日。

主要发现

  • AAO视网膜/玻璃体专家组评估70个临床问题,将17个(24%)评为高度重要。
  • 医生评估17个高度重要问题,将12个(71%)评为高优先级研究问题,其中9个与抗VEGF药物相关。
  • 患者将17个高度重要问题全部评为高优先级。
  • 患者从33个结局中确定6个(18%)最重要:脉络膜新生血管、进展为晚期AMD、视网膜出血、视力提高、减缓视力丧失和严重眼部事件。

关键数值与推荐

  • 12个高优先级临床问题被识别为AMD治疗研究的优先方向。
  • 6个患者最重要结局包括脉络膜新生血管、进展为晚期AMD、视网膜出血、视力提高、减缓视力丧失和严重眼部事件。

临床怎么用

  • 临床可参考12个优先研究问题关注AMD治疗中的关键不确定性,并重视患者认为重要的6个结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Identifying and prioritizing unanswered clinical questions may help to best allocate limited resources for research associated with the treatment of age-related macular degeneration (AMD). OBJECTIVE: To identify and prioritize clinical questions and outcomes for research associated with the treatment of AMD through engagement with professional and patient stakeholders. DESIGN, SETTING, AND PARTICIPANTS: Multiple cross-sectional survey questions were used in a modified Delphi process for panel members of US and international organizations, the American Academy of Ophthalmology (AAO) Retina/Vitreous Panel (n=7), health care professionals from the American Society of Retinal Specialists (ASRS) (n=90), Atlantic Coast Retina Conference (ACRC) and Macula 2017 meeting (n=34); and patients from MD (Macular Degeneration) Support (n=46). Data were collected from January 20, 2015, to January 9, 2017. MAIN OUTCOMES AND MEASURES: The prioritizing of clinical questions and patient-important outcomes for AMD. RESULTS: Seventy clinical questions were derived from the AAO Preferred Practice Patterns for AMD and suggestions by the AAO Retina/Vitreous Panel. The AAO Retina/Vitreous Panel assessed all 70 clinical questions and rated 17 of 70 questions (24%) as highly important. Health care professionals assessed the 17 highly important clinical questions and rated 12 of 17 questions (71%) as high priority for research to answer; 9 of 12 high-priority clinical questions were associated with aspects of anti-vascular endothelial growth factor agents. Patients assessed the 17 highly important clinical questions and rated all as high priority. Additionally, patients identified 6 of 33 outcomes (18%) as most important to them (choroidal neovascularization, development of advanced AMD, retinal hemorrhage, gain of vision, slowing vision loss, and serious ocular events). CONCLUSIONS AND RELEVANCE: Input from 4 stakeholder groups suggests good agreement on which 12 priority clinical questions can be used to underpin research related to the treatment of AMD. The 6 most important outcomes identified by patients were balanced between intended effects of AMD treatment (eg, slowing vision loss) and adverse events. Consideration of these patient-important outcomes may help to guide clinical care and future areas of research.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lindsley KB, Hutfless S, Hawkins BS, et al. Evaluation of Clinical Questions and Patient-Important Outcomes Associated With the Treatment of Age-Related Macular Degeneration. JAMA Ophthalmol. 2018. PMID: 30128539. doi:10.1001/jamaophthalmol.2018.3456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。